Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. MRNA has guided for 2025 revenues of $1.5B-$2.5B which doesn't seem to have ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

RSV Vaccines Effective ... VISION Network researchers report that across the board these ... New mRNA Vaccine Created to Prevent and Treat C. Difficile Oct. 17, 2024 — A new vaccine provides ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024 ... This figure includes a mere $10 million in sales of the new RSV vaccine following its third-quarter launch, underscoring the ...

Moderna's vaccine pipeline isn't likely to stop at flu, COVID, and RSV. A cytomegalovirus (CMV) vaccine candidate, mRNA-1647, is in the middle of a pivotal phase 3 trial that will read out results ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this one? The post Moderna’s meant to be a red-hot growth stock. What on earth’s ...